Delivery system for inhibiting PDGFR and application thereof
By using miR-144-3p and miR-451a as miRNAs that inhibit PDGFR, it uses AAV or plasmid vector to deliver to the liver to inhibit the expression of PDGFR, and solves the problems of side effects of existing drugs and poor inhibition effects, and achieves the liver Effective treatment and efficient delivery of fibrosis.
Patent Information
- Application Number
- CN202310661702.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-06
- Publication Date
- 2024-12-06
AI Technical Summary
Existing drugs for treating liver fibrosis have toxic side effects and are difficult to effectively inhibit the expression of PDGFR, making it difficult to control the progression of liver fibrosis.
Using a delivery system that inhibits PDGFR, miR-144-3p and miR-451a are used as miRNAs that inhibit PDGFR gene expression, and are delivered to the liver through adeno-associated virus (AAV) or plasmid vectors, inhibiting the expression of PDGFRα and PDGFRβ. This prevents the progression of liver fibrosis.
This method effectively reduces the expression of PDGFR in liver tissue, inhibits the liver fibrosis process, has high efficacy and almost no side reactions, and the delivery system based on plasmid vector is easy to be industrialized and large-scale purification, reducing production difficulty and cost.
Smart Images

Figure CN119074960A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a delivery system for inhibiting PDGFR and applications thereof. Technical Background
[0002] Chronic liver disease is one of the most important health problems in the world, with approximately 2 million people dying from liver disease each year. Potential causes of chronic liver disease include viral (HBV, HCV)-related chronic liver disease, alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH), as well as autoimmune and genetic diseases. Organ fibrosis is a characteristic of disease progression in chronic inflammatory diseases, accounting for 45% of all-cause mortality worldwide. Similarly, in the liver, the development of fibrosis mainly determines the quality of life and prognosis. In addition, the level of fibrosis is related to liver function and is a major risk factor for the development of hepatocellular carcinoma (HCC).
[0003] One approach to preventing mortality from liver-related diseases is to prevent the progression of fibrosis. Over the past few years, several in vitro and in vivo models have been developed to address the unmet medical need for developing highly effective and safe anti-fibrotic drugs. However, despite an increasing understanding of the molecular mechanisms of liver fibrosis, there are still few approved drugs for the treatment of liver fibrosis.
[0004] The development of liver fibrosis is accompanied by the gradual accumulation of extracellular matrix (ECM), which destroys the physiological structure of the liver. Disease factors such as liver viruses can cause damage to liver cells and mediate the infiltration of immune cells, thereby activating hepatic stellate cells (HSCs) to transdifferentiate into myofibroblasts, producing large amounts of collagen, and then participating in tissue repair. After short-term damage, this process is balanced by offsetting anti-fibrotic mechanisms. In contrast, in chronic liver disease, the imbalance between pro-fibrotic and anti-fibrotic mechanisms leads to the continuous activation of myofibroblasts, resulting in excessive production of ECM.
[0005] PDGF is a growth factor that promotes the division and proliferation of HSCs. Four distinct PDGF subunits have been identified, designated PDGF-A, -B, -C, and -D. These subunits can be linked by disulfide bonds to form five different polymers (PDGF-AA, -BB, -AB, -CC, and -DD), each exerting distinct functions. Binding of PDGFs to PDGFR induces PDGFR dimerization and phosphorylation, which in turn phosphorylates tyrosine residues on various intracellular substrates. PDGFR stimulation triggers the activation of several signaling pathways, including Ras / Raf signaling, phospholipase Cγ (PLCγ), the PI3K / Akt pathway, and the JAK / STAT pathway. These downstream components then activate the expression of profibrotic genes, such as type I collagen (COL1A1), inhibitors of metalloproteinases (TIMPs) and MMPs, and the apoptosis regulator Bcl2, leading to cell proliferation and survival. Currently, many drugs that regulate the PDGF signaling pathway have been used in preclinical and clinical studies, including Nilotinib, imatinib, etc., but these inhibitors have some toxic side effects. For example, animals treated with imatinib (20 mg / kg) showed a certain degree of hepatotoxicity.
[0006] Because miRNAs are closely related to the occurrence and development of various diseases, including tumors, they are also potential drug targets, and related clinical research has great application prospects. The basic concept of using miRNAs as drug targets is to identify miRNAs that increase or decrease sharply when the disease occurs, determine the effect of miRNAs on the disease, and then specifically inactivate miRNAs that perform "bad" functions in the body, that is, using miRNA antisense to silence miRNAs whose expression increases and promotes disease development; or to restore miRNAs that perform "good" functions, that is, using miRNA mimics to re-express miRNAs whose expression decreases and inhibits disease development, thereby balancing miRNA levels in the body and ultimately causing downstream target gene levels to return to normal, achieving the effect of treating the disease.
[0007] However, since RNA is easily degraded in the body, when antisense miRNA and miRNA analogs are used in vivo, they must be coupled with a protection and delivery system to ensure that the antisense miRNA and miRNA analogs are stable and effective in the body. Summary of the Invention
[0008] In view of the above-mentioned technical limitations, the present invention proposes a delivery system for inhibiting PDGFR and its application; it overcomes the deficiencies and defects mentioned in the background technology.
[0009] To achieve the above object, the present invention adopts the following technical solutions:
[0010] The inventive point of the present invention is to provide a delivery system for inhibiting PDGFR, which includes: RNA capable of inhibiting PDGFR gene expression and a delivery vector; the delivery vector carrying the RNA capable of inhibiting PDGFR gene expression self-assembles in the organ tissue of a mammal to form a composite structure, and the composite structure delivers the RNA capable of inhibiting PDGFR gene expression into the target tissue, thereby inhibiting the expression of PDGFR in the target tissue.
[0011] Optionally, in the above-mentioned delivery system for inhibiting PDGFR, the RNA capable of inhibiting PDGFR gene expression comprises: a promoter element and at least one miRNA capable of inhibiting PDGFR gene expression.
[0012] Optionally, in the above-mentioned delivery system for inhibiting PDGFR, the PDGFR gene includes a PDGFRα target gene and / or a PDGFRβ target gene.
[0013] Optionally, in the above-mentioned delivery system for inhibiting PDGFR, the miRNA capable of inhibiting PDGFR gene expression is composed of miR-144-3p and / or miR-451a, and their sequences are:
[0014] miR-144-3p (SEQ ID NO.1): UACAGUAUAGAUGAUGUACU;
[0015] miR-451a (SEQ ID NO.2): AAACCGUUACCAUUACUGAGUU;
[0016] The nucleotide sequence encoding the positive chain of miR-144-3p capable of inhibiting PDGFR gene expression is (SEQ ID NO.3):
[0017] 5'-ctggaggcttgctgaaggctgtatgctgaattcgtacagtatagatgatgtactgttttggccactgactgacagtacatcatatactgtacaccgg tcaggacacaaggcctgttactagcactcacatggaacaaatggcc-3';
[0018] The nucleotide sequence encoding the antisense strand of miR-144-3p capable of inhibiting PDGFR gene expression is (SEQ ID NO.4):
[0019] 5'- ggccatttgttccatgtgagtgctagtaacaggccttgtgtcctgaccggtgtacagtatatgatgtactgtcagtcagtggccaaaacagtacat catctatactgtacgaattcagcatacagccttcagcaagcctccag-3';
[0020] The nucleotide sequence encoding the sense strand of miR-451a capable of inhibiting PDGFR gene expression is (SEQ ID NO.5):
[0021] 5'- ctggaggcttgctgaaggctgtatgctgaattcgaaaccgttaccattactgagttgttttggccactgactgacaactcagtaatgaacggtttca ccggtcaggacacaaggcctgttactagcactcacatggaacaaatggcc-3';
[0022] The nucleotide sequence encoding the antisense strand of miR-451a capable of inhibiting PDGFR gene expression is (SEQ ID NO.6):
[0023] 5'- ggccatttgttccatgtgagtgctagtaacaggccttgtgtcctgaccggtgaaaccgttcattactgagttgtcagtcagtggccaaaacaactc agtaatggtaacggtttcgaattcagcatacagccttcagcaagcctccag-3'.
[0024] Optionally, in the above-mentioned delivery system for inhibiting PDGFR, the composite structure is an exosome, and the target tissue is activated hepatic stellate cells.
[0025] Optionally, in the above-mentioned delivery system for inhibiting PDGFR, the delivery vector is a plasmid vector or a viral vector; the viral vector includes at least one of a retroviral vector, a lentiviral vector, an adenoviral vector, and an adeno-associated viral vector, preferably an adenoviral vector.
[0026] The second invention of the present invention is to provide a use of the above-mentioned PDGFR inhibition delivery system in the preparation of a product for treating chronic liver disease, wherein the chronic liver disease is liver fibrosis.
[0027] Optionally, in the application, the product for treating chronic liver disease includes an agent that inhibits liver fibrosis or prevents PDGFR gene expression, or a drug that has a preventive and / or therapeutic effect on liver fibrosis.
[0028] Compared with the prior art, the present invention has the following advantages:
[0029] 1. The present invention provides for the first time two miRNAs whose expression decreases in liver tissue during the progression of liver fibrosis;
[0030] 2. It suggests that these two miRNAs can effectively inhibit the activation and transdifferentiation of hepatic stellate cells;
[0031] 3. These two miRNAs can specifically bind to the mRNA of PDGFRα and PDGFRβ genes, effectively inhibiting the expression of PDGFRα and PDGFRβ target genes;
[0032] 4. PDGFRα and PDGFRβ genes both play a role in promoting hepatic stellate cell activation during the progression of liver fibrosis. These two miRNAs have therapeutic value in liver fibrosis by inhibiting the expression of their target genes.
[0033] 5. Delivery of these two miRNAs to liver tissue via adeno-associated virus (AAV) can effectively inhibit the expression of PDGFRα and PDGFRβ genes in liver tissue, further inhibiting the progression of liver fibrosis and achieving the goal of treating liver fibrosis;
[0034] 6. This delivery system is based on synthetic biology components, using mammalian organs as natural bioreactors to express mature miRNA and encapsulate it into a composite structure that exerts its therapeutic effect in the target tissue with high efficacy and efficiency.
[0035] 7. This miRNA in vivo delivery system utilizes a naturally occurring secretion mechanism, thus avoiding the toxicity caused by other carriers, achieving high delivery efficiency and virtually no side effects.
[0036] 8. This miRNA in vivo delivery system is based on a plasmid vector, which is easy to industrialize and purify in large quantities. Compared with other miRNA delivery methods, it greatly reduces the production difficulty and cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 Shown is the plasmid map of CMV-miR-144-3p in one embodiment of the present invention.
[0038] Figure 2 Shown is the plasmid map of CMV-miR-451a in one embodiment of the present invention.
[0039] Figure 3 The results show that the expression levels of two miRNAs (miR-144 / 451a) in the liver tissue of mice were detected in the CCl4-induced mouse liver fibrosis model. Figure 3 a is the expression level of miR-144. Figure 3 b shows the expression level of miR-451a.
[0040] Figure 4 Shown is the detection of the expression levels of two miRNAs (miR-144 / 451a) in LX-2 cells. Figure 4 a is the expression level of miR-144. Figure 4 b shows the expression level of miR-451a.
[0041] Figure 5 The results show that two miRNAs (miR-144 / 451a) inhibit the activation of LX-2 cells. Figure 5 a is the Western Blot detection result of Collagen1 and α-SMA protein content in LX-2 cells. Figure 5 b shows that overexpression of two miRNAs significantly inhibited the protein expression of α-SMA. Figure 5 c shows that overexpression of two miRNAs significantly inhibited the protein expression of Collagen1. Figure 5 d: Overexpression of the two miRNAs significantly inhibited the mRNA expression of α-SMA. Figure 5 e shows that overexpression of two miRNAs significantly inhibited the mRNA expression of Collagen1; among them, the labels below the figure (TGF-β, NC mimic, miR-144 mimic, miR-451a mimic) are the reagent names, "-" indicates that this reagent / sample was not added during the treatment of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0042] Figure 6 The results show the calculation results of PDGFRα / β and miR-144 / 451a binding sites and binding energy. Figure 6 a is the result diagram of the interaction between miR-144 / 451a and PDGFRα, Figure 6 b is the result diagram of the interaction between miR-144 / 451a and PDGFRβ.
[0043] Figure 7 The figure shows the binding of miR-144 / 451a to PDGFRα / β mRNA verified by luciferase expression assay.
[0044] Figure 8The results show the detection of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum of mice using plasmid as the delivery vector. Figure 8 a is the level of alanine aminotransferase (ALT). Figure 8 b is the aspartate aminotransferase (AST) level; the labels below the figure (CCl4, NC vector, miR-144 mimic, miR-451a mimic) are the reagent names, "-" indicates that this reagent / sample was not added during the treatment of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0045] Figure 9 Shown are the results of HE staining (hematoxylin-eosin staining), Masson staining (trichrome staining), and picrosirius red staining of mouse liver tissue using plasmid as a delivery vector.
[0046] Figure 10 Shown are the expression levels of miR-144 and miR-451a in mouse liver tissue using plasmid as delivery vector. Figure 10 a is the expression level of miR-144. Figure 10 b shows the expression level of miR-451a; the labels below the figure (CCl4, NCvector, miR-144mimic, miR-451a mimic) are the reagent names, "-" indicates that this reagent / sample was not added during the treatment of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0047] Figure 11 Shown are the expression levels of α-SMA and Collagen1 in mouse liver tissue using plasmid as delivery vector. Figure 11 a is the Western Blot test result of Collagen1 and α-SMA protein content, Figure 11 b shows that the protein expression of Collagen1 was significantly inhibited after treatment with two miRNA plasmid vectors. Figure 11 c shows that the protein expression of α-SMA was significantly inhibited after treatment with two miRNA plasmid vectors. Figure 11 d shows that the mRNA expression of Collagen1 was significantly inhibited after treatment with two miRNA plasmid vectors. Figure 11 e shows that the mRNA expression of α-SMA was significantly inhibited after treatment with two miRNA plasmid vectors; among them, the labels below the figure (CCl4, NC vector, miR-144 mimic, miR-451a mimic) are the reagent names, "-" indicates that this reagent / sample was not added during the treatment of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0048] Figure 12The results show the detection of PDGFRα / β expression levels in mouse liver tissue using plasmid as delivery vector. Figure 12 a is the Western Blot detection result of PDGFRα / β protein expression level, Figure 12 b Compared with β-actin, the two miRNA plasmid vectors significantly inhibited the expression of PDGFRα after treatment. Figure 12 c Compared with β-actin, the two miRNA plasmid vectors significantly inhibited the expression of PDGFRβ after treatment. Figure 12 d Compared with GAPDH, the two miRNA plasmid vectors significantly inhibited the expression of PDGFRα after treatment. Figure 12 e shows that compared with GAPDH, the two miRNA plasmid vectors significantly inhibited the expression of PDGFRβ after treatment; among them, the labels below the figure (CCl4, NC vector, miR-144 mimic, miR-451a mimic) are the reagent names, "-" indicates that this reagent / sample was not added during the treatment of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0049] Figure 13 The results show the detection of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum of mice using AAV as the delivery vector. Figure 13 a is the level of alanine aminotransferase (ALT). Figure 13 b is the aspartate aminotransferase (AST) level; the labels below the figure (CCl4, AAV-scramble, AAV-miR-144, AAV-miR-451a) are the reagent names, "-" indicates that this reagent / sample was not added during the processing of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0050] Figure 14 Shown are the results of HE staining (hematoxylin-eosin staining), Masson staining (trichrome staining), and picrosirius red staining of mouse liver tissue using AAV as a delivery vector.
[0051] Figure 15 Shown are the expression levels of miR-144 and miR-451a in mouse liver tissue using AAV as a delivery vector. Figure 15 a is the expression level of miR-144. Figure 15 b shows the expression level of miR-451a; the labels below the figure (CCl4, AAV-scramble, AAV-miR-144, AAV-miR-451a) are the reagent names, "-" indicates that this reagent / sample was not added during the processing of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0052] Figure 16Shown are the expression levels of α-SMA and Collagen1 in mouse liver tissue using AAV as a delivery vector. Figure 16 a is the Western Blot test result of Collagen1 and α-SMA protein content, Figure 16 b shows that the protein expression of α-SMA was significantly inhibited after treatment with two miRNA virus AAV vectors. Figure 16 c shows that the protein expression of Collagen1 was significantly inhibited after treatment with two miRNA virus AAV vectors. Figure 16 d shows that the mRNA expression of α-SMA was significantly inhibited after treatment with two miRNA virus AAV vectors. Figure 16 e shows that the mRNA expression of Collagen1 was significantly inhibited after treatment with two miRNA virus AAV vectors; among them, the labels below the figure (CCl4, AAV-scramble, AAV-miR-144, AAV-miR-451a) are the reagent names, "-" indicates that this reagent / sample was not added during the treatment of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0053] Figure 17 Shown are representative images of immunohistochemical staining of Collagen 1 and α-SMA proteins in the liver tissue of mice using AAV as a delivery vector (scale bar: 100 μm).
[0054] Figure 18 The results show the quantitative immunohistochemical analysis of Collagen1 and α-SMA proteins in the liver tissue of mice using AAV as a delivery vector. Figure 18 a is the analysis result of Collagen1 protein, Figure 18 b is the analysis result of α-SMA protein; among them, the labels below the figure (CCl4, AAV-scramble, AAV-miR-144, AAV-miR-451a) are the reagent names, "-" indicates that this reagent / sample was not added during the processing of this group of samples, and "+" indicates that this reagent / sample was added to this group.
[0055] Figure 19 The results show the detection of PDGFRα / β expression levels in mouse liver tissue using AAV as a delivery vector. Figure 19 a is the Western Blot detection result of PDGFRα / β protein expression level, Figure 19 b Compared with β-actin, the two miRNA virus AAV vectors significantly inhibited the expression of PDGFRα after treatment. Figure 19 c Compared with β-actin, the two miRNA virus AAV vectors significantly inhibited the expression of PDGFRβ after treatment. Figure 19d Compared with GAPDH, the two miRNA virus AAV vectors significantly inhibited the expression of PDGFRα after treatment. Figure 19 e shows that compared with GAPDH, the two miRNA virus AAV vectors significantly inhibited the expression of PDGFRβ after treatment; among them, the labels below the figure (CCl4, AAV-scramble, AAV-miR-144, AAV-miR-451a) are the reagent names, "-" indicates that this reagent / sample was not added during the treatment of this group of samples, and "+" indicates that this reagent / sample was added to this group. DETAILED DESCRIPTION
[0056] To make the purpose, technical solutions and advantages of the present invention more clear, the present invention is further described in detail below. However, it should be understood that the description herein is only for explaining the present invention and is not intended to limit the scope of the present invention.
[0057] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention pertains. The terms used in the specification of the present invention are for the purpose of describing specific embodiments only and are not intended to limit the present invention. The reagents and instruments used herein are all commercially available. The characterization methods involved can be found in the relevant descriptions in the prior art and will not be described in detail herein.
[0058] In order to further understand the present invention, the present invention is further described in detail below in conjunction with the best embodiment. Example 1
[0059] A delivery system for inhibiting PDGFR, comprising: RNA capable of inhibiting PDGFR gene expression and a delivery vector; the delivery vector carrying the RNA capable of inhibiting PDGFR gene expression self-assembles in mammalian organ tissue to form a composite structure, and the composite structure delivers the RNA capable of inhibiting PDGFR gene expression into the target tissue, thereby inhibiting the expression of PDGFR in the target tissue.
[0060] In the delivery system, the RNA capable of inhibiting the expression of the PDGFR gene includes: a promoter element and at least one miRNA capable of inhibiting the expression of the PDGFR gene.
[0061] In the delivery system, the PDGFR gene includes a PDGFRα target gene and / or a PDGFRβ target gene.
[0062] In this delivery system, the miRNA nucleotides capable of inhibiting PDGFR gene expression are miR-144-3p and / or miR-451a, and their sequences are:
[0063] miR-144-3p (SEQ ID NO.1): UACAGUAUAGAUGAUGUACU;
[0064] miR-451a (SEQ ID NO.2): AAACCGUUACCAUUACUGAGUU;
[0065] The nucleotide sequence encoding the positive chain of miR-144-3p that can inhibit PDGFR gene expression is (SEQ ID NO.3):
[0066] 5'- ctggaggcttgctgaaggctgtatgctgaattcgtacagtatagatgatgtactgttttggccactgactgacagtacatcatatactgtacaccgg tcaggacacaaggcctgttactagcactcacatggaacaaatggcc-3';
[0067] The nucleotide sequence encoding the antisense strand of miR-144-3p that can inhibit PDGFR gene expression is (SEQ ID NO.4):
[0068] 5'- ggccatttgttccatgtgagtgctagtaacaggccttgtgtcctgaccggtgtacagtatatgatgtactgtcagtcagtggccaaaacagtacat catctatactgtacgaattcagcatacagccttcagcaagcctccag-3';
[0069] The nucleotide sequence encoding the sense strand of miR-451a that can inhibit PDGFR gene expression is (SEQ ID NO.5):
[0070] 5'- ctggaggcttgctgaaggctgtatgctgaattcgaaaccgttaccattactgagttgttttggccactgactgacaactcagtaatgaacggtttca ccggtcaggacacaaggcctgttactagcactcacatggaacaaatggcc-3';
[0071] The nucleotide sequence encoding the antisense strand of miR-451a that can inhibit PDGFR gene expression is (SEQ ID NO.6):
[0072] 5'- ggccatttgttccatgtgagtgctagtaacaggccttgtgtcctgaccggtgaaaccgttcattactgagttgtcagtcagtggccaaaacaactc agtaatggtaacggtttcgaattcagcatacagccttcagcaagcctccag-3'.
[0073] The above-mentioned miRNAs can bind to the common target genes PDGFRα and PDGFRβ mRNA and induce post-transcriptional gene silencing, thereby inhibiting the expression of PDGFRα and PDGFRβ.
[0074] In this delivery system, the composite structure is exosomes and the target tissue is activated hepatic stellate cells.
[0075] In the delivery system, the delivery vector is a plasmid vector or a viral vector; the viral vector includes at least one of a retroviral vector, a lentiviral vector, an adenoviral vector, and an adeno-associated viral vector, preferably an adenoviral vector.
[0076] The plasmid carries mature miRNAs: miR-144-3p and miR-451a. This plasmid molecule can be enriched in the liver tissue of mammals and spontaneously form exosomes in the liver tissue. The exosomes deliver miRNAs into activated hepatic stellate cells, thereby inhibiting the expression of target genes PDGFRα and PDGFRβ.
[0077] In practical applications, delivery systems (plasmid molecules) of miR-144-3p and miR-451a were constructed respectively. The promoter elements were connected in series with miR-144-3p / miR-451a and then connected to the backbone vectors respectively. The backbone structures of miR-144-3p and miR-451a plasmids are as follows: Figure 1 、 2 shown.
[0078] The plasmid sequences of miR-144-3p and miR-451a are specifically shown in SEQ ID NO.7 and SEQ ID NO.8.
[0079] SEQ ID NO.7(CMV-miR-144-3p):
[0080]
[0081] SEQ ID NO.8(CMV-miR-451a):
[0082] gacattgattattgactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaat gacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattacca tggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagt ttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggagg tctatataagcagagctctctggctaactagagaacccactgcttactggcttatcgaaattaatacgactcactatagggagtcccaagctggct agttaagctatcaacaagtttgtacaaaaaagcaggctttaaaaccgctaagcacttcgtggccgtcgatcgtttaaagggaggtagtgagtcga ccagtggatcctggaggcttgctgaaggctgtatgctgaattcgaaaccgttaccattactgagttgttttggccactgactgacaactcagtaat gaacggtttcaccggtcaggacacaaggcctgttactagcactcacatggaacaaatggcccagatctggccgcactcgagatatctagaccc agctttcttgtacaaagtggttgatctagagggcccgcggttcgctgatgggggaggctaactgaaacacggaaggagacaataccggaagg aacccgcgctatgacggcaataaaaagacagaataaaacgcacgggtgttgggtcgtttgttcataaacgcggggttcggtcccagggctgg cactctgtcgataccccaccgtgaccccattggggccaatacgcccgcgtttcttccttttccccaccccaccccccaagttcgggtgaaggcc cagggctcgcagccaacgtcggggcggcaggccctgccatagcatcccctatagtgagtcgtattacatggtcatagctgtttcctggcagctc tggcccgtgtctcaaaatctctgatggatctgcgcagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcg ggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgcc ggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgat ggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaac aacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacg cgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagt cagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcccgccc ctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcagaggccgaggcc gcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagcttgtatatccattttcg gatctgatcagcacggaagactacagcgtcgccagcgcagctctctctagcgacggccgcatcttcactggtgtcaatgtatatcattttactgg gggaccttgtgcagaactcgtggtgctgggcactgctgctgctgcggcagctggcaacctgacttgtatcgtcgcgatcggaaatgagaacag gggcatcttgagcccctgcggacggtgccgacaggtgcttctcgatctgcatcctgggatcaaagccatagtgaaggacagtgatggacagc cgacggcagttgggattcgtgaattgctgccctctggttatgtgtgggagggctaagcacttcgtggccgaggagcaggactgacacgtgcta cgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttccgggacgccggctggatgatcctccagcgcggggatc tcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttt tttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctgtataccgtcgctcttccgctgcttcctcgctcactgactcgctg cgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaaga acatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcat cacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctc tcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagtt cggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtc caacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttct tgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagc tcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatc ctttgatcttttctacggggtctgacgctcagtggaacgacgcgtaactcacgttaagggattttggtcatgggtggctcgacgagggttatttgcc gactaccttggtgatctcgcctttcacgtagtggacaaattcttccaactgatctgcgcgcgaggccaagcgatcttcttcttgtccaagataagcc tgtctagcttcaagtatgacgggctgatactgggccggcaggcgctccattgcccagtcggcagcgacatccttcggcgcgattttgccggtta ctgcgctgtaccaaatgcgggacaacgtaagcactacatttcgctcatcgccagcccagtcgggcggcgagttccatagcgttaaggtttcattt agcgcctcaaatagatcctgttcaggaaccggatcaaagagttcctccgccgctggacctaccaaggcaacgctatgttctcttgcttttgtcag caagatagccagatcaatgtcgatcgtggctggctcgaagatacctgcaagaatgtcattgcgctgccattctccaaattgcagttcgcgcttag ctggataacgccacggaatgatgtcgtcgtgcacaacaatggtgacttctacagcgcggagaatctcgctctctccaggggaagccgaagttt ccaaaaggtcgttgatcaaagctcgccgcgttgtttcatcaagccttacggtcaccgtaaccagcaaatcaatatcactgtgtggcttcaggccg ccatccactgcggagccgtacaaatgtacggccagcaacgtcggttcgagatggcgctcgatgacgccaactacctctgatagttgagtcgat acttcggcgatcaccgcttccctcataatgtttaactttgttttagggcgactgccctgctgcgtaacatcgttgctgctccataacatcaaacatcg acccacggcgtaacgcgcttgctgcttggatgcccgaggcatagactgtaccccaaaaaaacagtcataacaagccatgaaaaccgccactg cgccgttaccaccgctgcgttcggtcaaggttctggaccagttgcgtgagcgcatacgctacttgcattacagcttacgaaccgaacaggcttat gtccactgggttcgtgccttcatccgtttccacggtgtgcgtcacccggcaaccttgggtagcagcgaagtcgaggcatttctgtcctggctggtctagaattgcatgaagaatctgcttagggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgtt.
[0083] The delivery system based on plasmid vectors is easier to produce and purify on a large scale industrially. Compared with other miRNA delivery systems, the production difficulty and cost are greatly reduced.
[0084] The application of the above-mentioned PDGFR inhibition delivery system in the preparation of products for treating chronic liver diseases, especially in the preparation of products for treating liver fibrosis.
[0085] Products for the treatment of chronic liver diseases include agents that inhibit liver fibrosis or block PDGFR gene expression, and drugs that have preventive and / or therapeutic effects on liver fibrosis. Example 2
[0086] Based on Example 1, this example further uses adeno-associated virus (AAV) as a delivery vector.
[0087] Compared with the plasmid vector in Example 1, the delivery vector only needs one injection to achieve spontaneous expression of miRNA in vivo without the need for multiple injections.
[0088] This miRNA delivery system is used in the treatment of liver fibrosis. It is non-toxic, has no side effects, is fast-acting, has good efficacy, and is suitable for large-scale promotion and use. Example 3
[0089] The model construction, experimental methods and detection methods involved in this experiment are specifically shown below.
[0090] 1. Construction and validation of liver fibrosis mouse model:
[0091] A CCl4-induced liver fibrosis mouse model was established. After establishment, liver tissue was harvested and total RNA was extracted using Trizol reagent. Subsequently, reverse transcription-PCR (RT-PCR) and real-time quantitative PCR (qPCR) were used for detection. RT-qPCR was used to detect miR-144 / 451a, whose expression was significantly reduced in the liver tissue of mice with liver fibrosis.
[0092] Liver tissue miRNA was reverse transcribed using the system shown in Table 1 below (10 μL).
[0093] Table 1 Reagents Volume (μL) AMV reverse transcriptase 0.5 dNTP Mixture 1 5×AMV buffer 2 Reverse transcription primers 1 DEPC water 4.5 RNA 1 Total 10.0μL
[0094] After the system is configured, mix well and place in a PCR instrument for reaction. The reaction procedure is as shown in the miRNA reverse transcription procedure in Table 2.
[0095] Table 2 temperature time 16℃ 30min 42℃ 30min 85℃ 5min 4℃ ∞
[0096] After reverse transcription is completed, qPCR primers are used for quantitative detection. The qPCR system is shown in the miRNA qPCR system (20 μL).
[0097] Table 3
[0098] The qPCR program is shown in Table 4.
[0099] Table 4
[0100] 2. Luciferase reporter assay demonstrated the inhibitory effect of miR-144 / 451a on target genes:
[0101] Sequence fragments of the target genes PDGFRα and PDGFRβ that bind to miR-144 / 451a were inserted into the pMIR-REPORT Luciferase plasmid to construct luciferase reporter plasmids for each gene. Positive clones were screened and sequenced, amplified, and the plasmids purified. The relevant cells were cultured and seeded in 24-well plates. 12-16 hours later, the cells were co-transfected with a luciferase expression plasmid containing the predicted target gene and miR-144 / 451a. 24 hours later, the cells were harvested and lysed, and luciferase substrate was added. Luciferase reacted with the substrate to produce luciferin. By measuring the fluorescence intensity, luciferase activity was measured and compared with the nonsense RNA transfection group to determine whether the predicted target was inhibited by the Angong Niuhuang Wan microRNA.
[0102] 3. Cell experiments demonstrated that miR-144 / 451a inhibits the activation of hepatic stellate cells by suppressing the expression of PDGFRα and PDGFRβ:
[0103] Human hepatic stellate cells (LX-2) were activated by TGF-β. After 24 hours, cells were harvested for RNA and protein extraction. RT-qPCR was used to detect miR-144 / 451a expression in activated LX-2 cells. LX-2 cells were then transfected with miR-144 mimics, miR-451a mimics, and NC mimics using Lipo3000. LX-2 cells were then activated by TGF-β. After 24 hours, cells were harvested for RNA and protein extraction. RT-qPCR was used to detect Collagen1 and α-SMA mRNA expression in activated LX-2 cells. Western Blot was used to detect Collagen1, α-SMA, PDGFRα, and PDGFRβ protein expression in LX-2 cells.
[0104] 4. Study on the efficacy of plasmid-delivered miR-144 / 451a in the treatment of liver fibrosis:
[0105] Wild-type C57BL6 / J mice were randomly divided into five groups. One group of mice was intraperitoneally injected with olive oil as a control, and the other mice were injected with CCl4 to establish a liver fibrosis model. On the seventh day of modeling, the control mice were injected with PBS, and the other mice were injected with NC vector, miR-144 vector, miR-451a vector, and miR-144 vector + miR-451a vector, respectively. The injection dose was 5 mg / kg, and the injection was once every two days. After 10 injections, the mice were killed, and serum and liver tissues were collected. First, serum ALT and AST levels were measured in each group of mice. The progression of liver fibrosis in each group of mice was then assessed using HE, Masson's, and picrosirius red staining. The expression levels of miR-144 / 451a in liver tissue were detected by quantitative PCR. The expression levels of Collagen1 and α-SMA proteins were then measured by Western blotting, and the expression levels of Collagen1 and α-SMA mRNA in liver tissue were also measured by quantitative PCR. Finally, the expression levels of PDGFRα / β proteins in liver tissue were measured by Western blotting. This demonstrates that plasmid delivery of miR-44 / 451a can effectively inhibit the expression of PDGFRα / β in mouse liver tissue, thereby exerting a therapeutic effect on liver fibrosis.
[0106] 5. Animal experiments to evaluate the therapeutic effect of AAV-delivered miR-144 / 451a on liver fibrosis:
[0107] Wild-type C57BL6 / J mice were randomly divided into five groups and injected with PBS, AAV-scramble RNA, AAV-miR-144, AAV-miR-451a, and AAV-miR-144+AAV-miR-451a, respectively, with an injection dose of 1×1011 v.g per mouse. Seven days after injection, the mice were subjected to liver fibrosis modeling. After the modeling was completed, the mice were killed, and serum and liver tissue were collected. First, the serum ALT and AST levels of mice in each group were measured. The progression of liver fibrosis in each group was then assessed using HE, Masson's, and picrosirius red staining. The expression levels of miR-144 / 451a in liver tissue were detected by quantitative PCR. The expression levels of Collagen1 and α-SMA proteins were then measured by Western Blot, and the expression levels of Collagen1 and α-SMA mRNA in liver tissue were also measured by quantitative PCR. Finally, the expression levels of PDGFRα / β proteins in liver tissue were measured by Western Blot and immunohistochemistry. Ultimately, it was demonstrated that AAV delivery of miR-44 / 451a effectively inhibited the expression of PDGFRα / β in mouse liver tissue, thereby exerting a therapeutic effect on liver fibrosis. Test Example 1
[0108] A CCl4-induced mouse liver fibrosis model was established. CCl4 and olive oil were prepared in a ratio of 1:4. CCl4 and olive oil diluted in olive oil were injected intraperitoneally into 8-week-old wild-type mice, respectively, at a dose of 100 μL / mouse once every three days for 10 injections. One day after the last injection, the mice were killed, and liver tissues were taken to extract RNA. The expression of miR-144 / 451a in the liver tissues was detected. The test results are as follows: Figure 3 As shown, Figure 3 a is the expression level of miR-144. Figure 3 b shows the expression level of miR-451a. Test Example 2
[0109] This example demonstrates that miR-144 / 451a can inhibit the activation of hepatic stellate cells at the cellular level; TGF-β was used to induce activation of human hepatic stellate cells LX-2. LX-2 cells were cultured in a medium containing 10 ng / mL TGF-β and a medium without TGF-β, respectively. After 24 hours, the cells were collected and RNA was extracted. Furthermore, the expression level of miR-144 / 451a in LX-2 cells was detected by fluorescence quantitative PCR. Figure 4 As shown in the figure, the results showed that the expression of miR-144 / 451a in activated LX-2 cells was significantly decreased compared with that in unactivated LX-2 cells.
[0110] LX-2 cells were transfected with Lipo3000 and transfected with mimic NC, miR-144 mimic, miR-451 mimic, and co-transfected with miR-144 mimic and miR-451a mimic. Six hours after transfection, LX-2 cells were stimulated with TGF-β. 24 hours later, cells were collected to extract protein and RNA. Western Blot was used to detect the protein levels of Collagen1 and α-SMA in LX-2 cells. Then, quantitative PCR was used to detect the mRNA expression levels of Collagen1 and α-SMA in LX-2 cells. Overexpression of miR-144 and miR-451a significantly inhibited the protein and mRNA expression of Collagen1 and α-SMA. Figure 5 As shown in the results, when miR-144 and miR-451a were co-overexpressed, the inhibition efficiency of Collagen1 and α-SMA was relatively better, which indicated that miR-144 and miR-451a could inhibit the activation of LX-2 cells by TGF-β. Test Example 3
[0111] Three computational algorithms, TargetScan, PicTar, and miRanda, were used to predict potential target genes of miR-144 / 451a. The results showed that PDGFR (PDGFRα, PDGFRβ), growth factors that promote HSC division, proliferation, and transdifferentiation, may be common target genes of miR-144 / 451a. The interaction between miR-144 / 451a and target sites in PDGFRα and PDGFRβ 3'-UTR is shown in Figure 2. Figure 6 As shown in Figure 2, the 3'-UTRs of PDGFRα and PDGFRβ both contain conserved binding sites for miR-144 / 451a. Good base pairing exists between the miR-144 / 451a seed sequence and the PDGFRα and PDGFRβ mRNAs, with minimum free energy values less than -20.0 kcal / mol, consistent with the binding conditions of classic miRNAs for target genes.
[0112] Then, in order to verify whether miR-144 / 451a directly binds to the 3'-UTR region of the target gene mRNA and regulates the expression of PDGFRα and PDGFRβ, the binding site sequence on the predicted target gene mRNA was designed downstream of the firefly luciferase gene in the luciferase reporter plasmid, and a plasmid vector (WT) was constructed. If the miRNA directly binds to the site sequence, the expression of the downstream luciferase can be inhibited; correspondingly, if the binding site is mutated (MUT), the miRNA cannot affect the expression of luciferase. The recombinant plasmid was co-transfected with miR-144 mimics, miR-451a mimics and mimics NC into HEK293T cells, and the luciferase fluorescence signal was detected after 24 hours. The results are shown in Figure 2. Figure 7 As shown in the results, miR-144 and miR-451a inhibited the expression of luciferase in the WT plasmid vector by about 50%, but had no obvious inhibitory effect on the MUT plasmid vector, proving that miR-144 and miR-451a can directly bind to the 3'-UTR region of PDGFRα and PDGFRβ, thereby inhibiting the expression of PDGFRα and PDGFRβ. Test Example 4
[0113] This example demonstrates that using miR-144 / 451 plasmids to deliver miR-144 / 451a, which is reduced in liver tissue during the progression of liver fibrosis, can effectively inhibit the progression of liver fibrosis. Wild-type C57BL6 / J mice were randomly divided into five groups, four of which were treated with CCl4 to establish a liver fibrosis model, and the remaining group of mice received an intraperitoneal injection of olive oil as a control. The four groups of mice were injected with NC vector, miR-144 vector, miR-451a vector, and miR-144 vector + miR-451a vector, respectively, at a dose of 5 mg / kg for 15 injections. The mice were then sacrificed and serum and liver tissue were collected. First, the levels of ALT and AST in the serum of mice in each group were detected. After the model was established, the ALT and AST levels in the serum of mice injected with NC vector were significantly higher than those in healthy mice, while the ALT and AST levels in the serum of mice injected with miR-144 vector, miR-451a vector, and miR-144 vector + miR-451a vector were significantly reduced, significantly lower than those in the NC vector group, and approaching the levels of healthy mice. The results are as follows Figure 8 shown.
[0114] Then, HE, Masson and picrosirius red staining were used to evaluate the disease progression of liver fibrosis in each group of mice. Figure 9The results also showed that the content of collagen fibers in the liver tissue of mice injected with miR-144 vector, miR-451a vector, and miR-144 vector + miR-451a vector was significantly lower than that of mice injected with NC vector.
[0115] The expression levels of miR-144 / 451a in liver tissue were detected by fluorescence quantitative PCR. After CCl4 induction, the expression of miR-144 / 451a in mouse liver tissue was significantly reduced. After treatment with miR-144 vector, miR-451a vector, and miR-144 vector + miR-451a vector, the expression levels of miR-144 and miR-451a in liver tissue of mice returned to the levels of healthy mice or even higher. The results are as follows Figure 10 shown.
[0116] Then, the expression levels of Collagen1 and α-SMA proteins were detected by Western Blot. After treatment with miR-144 vector, miR-451a vector, and miR-144 vector + miR-451a vector, the expression of Collagen1 and α-SMA proteins in the liver tissue of mice was significantly inhibited. Then, the expression levels of Collagen1 and α-SMA mRNA in the liver tissue were detected by fluorescence quantitative PCR. Figure 11 The results showed that, consistent with the protein expression pattern, after restoring the expression of miR-144 and miR-451a, the expression of Collagen1 and α-SMA mRNA was significantly reduced. Among them, restoring the expression of the two miRNAs at the same time had a better inhibitory effect on Collagen1 and α-SMA.
[0117] Finally, the expression levels of PDGFRα / β proteins in liver tissue were detected by Western Blot. Figure 12 The results showed that the treatment of miR-144 vector, miR-451a vector, and miR-144 vector + miR-451a vector effectively inhibited the expression of PDGFRα / β protein; the results of fluorescence quantitative PCR also proved that the expression of PDGFRα / β mRNA was significantly reduced after the expression of miR-144 and miR-451a was restored. Test Example 5
[0118] This example demonstrates that the use of AAV to deliver miR-144 / 451a, which is reduced in liver tissue during the process of liver fibrosis, can effectively inhibit the progression of liver fibrosis. First, wild-type C57BL6 / J mice were randomly divided into five groups and injected with PBS, AAV-scramble RNA, AAV-miR-144, AAV-miR-451a, and AAV-miR-144+AAV-miR-451a, respectively. The injection dose was 1×10 per mouse. 11 vg; Seven days after injection, mice were modeled for liver fibrosis; after modeling, the mice were killed and serum and liver tissues were collected. First, the levels of ALT and AST in the serum of mice in each group were detected. After modeling, the ALT and AST levels in the serum of mice injected with AAV-scramble RNA were significantly higher than those in healthy mice, while the ALT and AST levels in the serum of mice injected with AAV-miR-144, AAV-miR-451a, and AAV-miR-144+AAV-miR-451a were significantly reduced, significantly lower than those in the AAV-scramble RNA group, and approaching the levels of healthy mice. Figure 13 shown.
[0119] Then, HE, Masson and picrosirius red staining were used to evaluate the disease progression of liver fibrosis in each group of mice. Figure 14 The results also showed that the content of collagen fibers in the liver tissue of mice injected with AAV-miR-144, AAV-miR-451a, and AAV-miR-144+AAV-miR-451a was significantly lower than that of mice injected with AAV-scramble RNA.
[0120] The expression levels of miR-144 / 451a in liver tissue were detected by fluorescence quantitative PCR. After CCl4 induction, the expression of miR-144 / 451a in mouse liver tissue was significantly reduced. Injection of AAV-miR-144 and AAV-miR-451a could restore the expression levels of miR-144 and miR-451a in mouse liver tissue to the levels of healthy mice or even higher. Figure 15 shown.
[0121] Then, the expression levels of Collagen1 and α-SMA proteins were detected by Western Blot. The results showed that after AAV restored the expression of miR-144 and miR-451a in the liver, the expression of Collagen1 and α-SMA proteins in the liver tissue of mice was significantly inhibited. Afterwards, the expression levels of Collagen1 and α-SMA mRNA in the liver tissue were detected by fluorescent quantitative PCR. Figure 16The results showed that, consistent with the protein expression pattern, after restoring the expression of miR-144 and miR-451a, the expression of Collagen1 and α-SMA mRNA was significantly reduced. Among them, restoring the expression of the two miRNAs at the same time had a better inhibitory effect on Collagen1 and α-SMA.
[0122] Figure 17 and Figure 18 The immunohistochemistry results shown in the figure showed that after CCl4 induction, the levels of α-SMA and Collagen1 in the liver tissue of mice injected with AAV-scramble were significantly increased. In comparison, the accumulation of α-SMA and Collagen1 in the liver tissue of mice injected with AAV-miR-144 and AAV-miR-451a was significantly inhibited, and the effect was most obvious in mice injected with the two AAVs together.
[0123] Finally, the expression levels of PDGFRα / β proteins in liver tissue were detected by Western Blot. Figure 19 The results showed that the injection of AAV-miR-144 and AAV-miR-451a effectively inhibited the expression of PDGFRα / β protein; the results of fluorescence quantitative PCR also proved that the expression of PDGFRα / β mRNA was significantly reduced after the expression of miR-144 and miR-451a was restored.
[0124] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A delivery system for inhibiting PDGFR, characterized in that: The delivery system comprises: RNA capable of inhibiting PDGFR gene expression and a delivery vector; the delivery vector carrying the RNA capable of inhibiting PDGFR gene expression self-assembles in the organ tissue of a mammal to form a composite structure, and the composite structure delivers the RNA capable of inhibiting PDGFR gene expression into the target tissue to inhibit the expression of PDGFR in the target tissue.
2. The PDGFR-inhibiting delivery system according to claim 1, characterized in that: The RNA capable of inhibiting the expression of the PDGFR gene comprises: a promoter element and at least one miRNA capable of inhibiting the expression of the PDGFR gene.
3. The PDGFR-inhibiting delivery system according to claim 2, characterized in that: The PDGFR gene includes a PDGFRα target gene and / or a PDGFRβ target gene.
4. The PDGFR-inhibiting delivery system according to claim 3, characterized in that: The miRNA nucleotides capable of inhibiting PDGFR gene expression are miR-144-3p and / or miR-451a, and their sequences are: miR-144-3p:UACAGUAUAGAUGAUGUACU; miR-451a: AAACCGUUACCAUUACUGAGUU; The nucleotide sequence encoding the sense strand of miR-144-3p capable of inhibiting PDGFR gene expression is: 5’- ctggaggcttgctgaaggctgtatgctgaattcgtacagtatagatgatgtactgttttggccactgactgacagtacatcat atactgtacaccggtcaggacacaaggcctgttactagcactcacatggaacaaatggcc-3'; The nucleotide sequence encoding the antisense strand of miR-144-3p capable of inhibiting PDGFR gene expression is: 5’- ggccatttgttccatgtgagtgctagtaacaggccttgtgtcctgaccggtgtacagtatatgatgtactgtcagtcagtggc caaaacagtacatcatctatactgtacgaattcagcatacagccttcagcaagcctccag-3'; The nucleotide sequence encoding the sense strand of miR-451a capable of inhibiting PDGFR gene expression is: 5'- ctggaggcttgctgaaggctgtatgctgaattcgaaaccgttaccattactgagttgttttggccactgactgacaactcagt aatgaacggtttcaccggtcaggacacaaggcctgttactagcactcacatggaacaaatggcc-3'; The nucleotide sequence encoding the miR-451a antisense strand capable of inhibiting PDGFR gene expression is: 5'- ggccatttgttccatgtgagtgctagtaacaggccttgtgtcctgaccggtgaaaccgttcattactgagttgtcagtcagtg gccaaaacaactcagtaatggtaacggtttcgaattcagcatacagccttcagcaagcctccag-3'.
5. The PDGFR-inhibiting delivery system according to claim 1, characterized in that: The composite structure is an exosome.
6. The PDGFR inhibition delivery system according to claim 1, characterized in that: The delivery vector is a plasmid vector or a viral vector; the viral vector includes at least one of a retroviral vector, a lentiviral vector, an adenoviral vector, and an adeno-associated viral vector.
7. Use of the PDGFR-inhibiting delivery system according to any one of claims 1 to 6 in the preparation of a product for treating chronic liver disease, characterized in that: The chronic liver disease is a liver fibrosis disorder.
8. The use according to claim 7, characterized in that: The products for treating chronic liver diseases include agents for inhibiting liver fibrosis or preventing PDGFR gene expression, and drugs having preventive and / or therapeutic effects on liver fibrosis.
